Chelsea M. Mclean

Leiden, ZH, Netherlands

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 29 publications

Correction: Leroux-Roels et al. Immunogenicity and Safety of the ExPEC9V Escherichia coli Vaccine Co-Administered with a High-Dose Influenza Vaccine in Older Adults: A Placebo-Controlled, Randomized, Phase 3 Study. Vaccines 2026, 14, 146.

Correction: Leroux-Roels et al. Immunogenicity and Safety of the ExPEC9V Escherichia coli Vaccine Co-Administered with a High-Dose Influenza Vaccine in Older Adults: A Placebo-Controlled, Randomized, Phase 3 Study. Vaccines 2026, 14, 146.

Journal: Vaccines
Published: May 06, 2026

Immunogenicity and Safety of the ExPEC9V Escherichia coli Vaccine Co-Administered with a High-Dose Influenza Vaccine in Older Adults: A Placebo-Controlled, Randomized, Phase 3 Study.

Immunogenicity and Safety of the ExPEC9V Escherichia coli Vaccine Co-Administered with a High-Dose Influenza Vaccine in Older Adults: A Placebo-Controlled, Randomized, Phase 3 Study.

Journal: Vaccines
Published: December 22, 2025

A group 1 hemagglutinin stem vaccine elicits broad humoral responses against influenza in phase 1/2a study.

A group 1 hemagglutinin stem vaccine elicits broad humoral responses against influenza in phase 1/2a study.

Journal: Nature communications
Published: December 19, 2025

The role of naturally occurring and vaccine-induced Ad26 neutralizing antibodies in immunogenicity of Ad26-based vaccines.

The role of naturally occurring and vaccine-induced Ad26 neutralizing antibodies in immunogenicity of Ad26-based vaccines.

Journal: NPJ vaccines
Published: December 05, 2025

A randomized, observer-blind, phase 1 study of immune responses to three human adenovirus type 26 vector-based vaccines.

A randomized, observer-blind, phase 1 study of immune responses to three human adenovirus type 26 vector-based vaccines.

Journal: EBioMedicine
Published: July 30, 2025

Early transcriptional responses following Ad26.COV2.S vaccination in individuals with prior SARS-CoV-2 infection.

Early transcriptional responses following Ad26.COV2.S vaccination in individuals with prior SARS-CoV-2 infection.

Journal: EBioMedicine
Published: June 26, 2025

Ebola virus vaccination elicits Ebola virus-specific immune responses without substantial cross-reactivity to other filoviruses.

Ebola virus vaccination elicits Ebola virus-specific immune responses without substantial cross-reactivity to other filoviruses.

Journal: Science translational medicine
Published: April 02, 2025

Heterologous two-dose Ebola vaccine regimen in pregnant women in Rwanda: a randomized controlled phase 3 trial.

Heterologous two-dose Ebola vaccine regimen in pregnant women in Rwanda: a randomized controlled phase 3 trial.

Journal: Nature medicine
Published: February 06, 2025

Immunogenicity of an Extended Dose Interval for the Ad26.ZEBOV, MVA-BN-Filo Ebola Vaccine Regimen in Adults and Children in the Democratic Republic of the Congo.

Immunogenicity of an Extended Dose Interval for the Ad26.ZEBOV, MVA-BN-Filo Ebola Vaccine Regimen in Adults and Children in the Democratic Republic of the Congo.

Journal: Vaccines
Published: May 25, 2024

Lot-to-lot consistency, immunogenicity, and safety of the Ad26.ZEBOV, MVA-BN-Filo Ebola virus vaccine regimen: A phase 3, randomized, double-blind, placebo-controlled trial.

Lot-to-lot consistency, immunogenicity, and safety of the Ad26.ZEBOV, MVA-BN-Filo Ebola virus vaccine regimen: A phase 3, randomized, double-blind, placebo-controlled trial.

Journal: Human vaccines & immunotherapeutics
Published: March 25, 2024

Safety and Immunogenicity of Accelerated Heterologous 2-Dose Ebola Vaccine Regimens in Adults With and Without HIV in Africa.

Safety and Immunogenicity of Accelerated Heterologous 2-Dose Ebola Vaccine Regimens in Adults With and Without HIV in Africa.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: December 01, 2023

Ad26.ZEBOV, MVA-BN-Filo Ebola virus disease vaccine regimen plus Ad26.ZEBOV booster at 1 year versus 2 years in health-care and front-line workers in the Democratic Republic of the Congo: secondary and exploratory outcomes of an open-label, randomised, phase 2 trial.

Ad26.ZEBOV, MVA-BN-Filo Ebola virus disease vaccine regimen plus Ad26.ZEBOV booster at 1 year versus 2 years in health-care and front-line workers in the Democratic Republic of the Congo: secondary and exploratory outcomes of an open-label, randomised, phase 2 trial.

Journal: The Lancet. Infectious diseases
Published: October 12, 2023
Showing 1-12 of 29

Last Updated: 09/26/2026